Hosted on MSN10mon
AstraZeneca follows rival, will cap inhaler prices at $35 per month amid scrutiny
(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
pharmaphorum2y
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
PT027 and the albuterol comparator were delivered in a pressurised metered-dose inhaler using AstraZeneca’s Aerosphere delivery technology. Results showed that PT027 at the 180mcg albuterol ...
pharmaphorum2d
AstraZeneca, Honeywell partner to address climate change with new inhaler tech
UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...
STAT5d
Pharmalittle: We’re reading about Trump rescinding drug-pricing tests, a Walgreens opioid suit, and more
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
Pharmaceutical Technology9d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
The Financial Express7d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...